V8 Peptides — Engineered Performance
Research Library
Hexarelin and IGF-1: What Preclinical Studies Report
HexarelinPreclinical

Hexarelin and IGF-1: What Preclinical Studies Report

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

In the preclinical papers reviewed here, hexarelin reliably stimulated growth hormone release in rats and dogs, but circulating IGF-1 was reported as unchanged in aged rats (30 and 60 days), aged dogs (16 weeks), obese melanocortin-4-receptor-knockout mice and was not recovered in streptozotocin-diabetic rats. The likeliest reasons are repeated-exposure desensitization of the GH response, loss of pulsatile signal quality, and model-specific physiology. A study that wants to read out IGF-1 therefore needs a defined schedule, a sampling plan that matches the biology of the axis, and a validated assay. For laboratory research use only; not for human consumption.

Growth hormone secretagogues are often described as acting through a simple chain: receptor activation, pituitary GH release, hepatic IGF-1. The animal data for hexarelin show that the first link is robust and the last link is not. This article reads the primary rat, dog and mouse papers on that point, lays out what each reported, and then turns the observation into design advice for a laboratory that wants to measure IGF-1 itself. It describes preclinical work only. The compound is the research material on the hexarelin product page, and its receptor pharmacology is covered in the hexarelin research overview.

The axis the question depends on

Hexarelin is a GHRP-family hexapeptide that acts at GHS-R1a on pituitary somatotrophs and hypothalamic neurons. In a classical view, a rise in GH is followed by a rise in IGF-1, the liver-derived mediator that is the usual circulating marker of GH action. Whether that chain holds for a given secretagogue is an empirical question that depends on how much GH is released, how it is patterned over time, and the physiological state of the animal.

Hexarelin is a useful test case because it is potent and because its GH effect is well characterized in several species (Conley and colleagues, 1998; Cattaneo and colleagues, 1997). If IGF-1 failed to follow GH here, the explanation could not be that the secretagogue was weak. The papers below are the ones that measured both.

Study-by-study evidence

StudyModel and scheduleGH findingIGF-1 finding
Cattaneo and colleagues, 1997Aged rats, 80 µg/kg s.c. for 30 and 60 daysGH-releasing effect maintained; hypothalamic somatostatin mRNA brought to young-animal levelsCirculating IGF-1 not altered
Cella and colleagues, 1996Aged beagles, 500 µg/kg per day, 16 weeks in three on-periodsGH peak rose, then returned to pretreatment values in each period; spontaneous pulsatility indices increasedPlasma IGF-I did not change
Rigamonti and colleagues, 1999Young beagles, 250 µg/kg twice daily, 6 weeksGH response to challenge rose then fell by week 6Not the paper's focus; response pattern is the finding
Zhang and colleagues, 2018Streptozotocin-diabetic rats, 100 µg/kg daily, 2 weeksTotal, pulsatile and basal GH secretion increasedIGF-1 remained suppressed
Huang and colleagues, 2021Obese MC4RKO mice, 10.56 µg/day by osmotic pump, 3–4 weeksPulsatile GH secretion increased; basal GH unchangedIGF-1 levels not altered

Across species, ages and disease models the pattern is consistent: GH output was increased, IGF-1 was not. Rat and dog data from the 1990s and rat and mouse data from 2018 and 2021 reach the same observation, which makes it unlikely to be a quirk of one laboratory.

Why GH release and IGF-1 can diverge

The papers themselves point to several non-exclusive explanations. None of them is proven for hexarelin; they are the hypotheses the data support.

  • Desensitization. Repeated exposure reduces the GH response. In rats, a second bolus two hours after the first gave a smaller peak, and continuous infusion raised GH only briefly (Conley and colleagues, 1998). In dogs the challenge response rose then fell within six weeks (Rigamonti and colleagues, 1999). If the net weekly GH exposure does not rise, IGF-1 has no reason to.
  • Pattern, not just quantity. The mouse obesity paper emphasized pulsatile secretion without a change in basal GH (Huang and colleagues, 2021). A pulse-driven axis can raise tissue-level GH signaling in fat and liver without changing the circulating IGF-1 reading.
  • Baseline physiology. In the diabetic rat model GH was low and IGF-1 was low; hexarelin restored GH secretion but not IGF-1 (Zhang and colleagues, 2018). The authors link the diabetic state to the impaired axis, so IGF-1 recovery may need more than a restored GH signal.
  • Measurement window. A single blood draw reflects one point in a long, slowly changing pool. IGF-1 has a longer time constant than GH, so a short study may simply end before a change could be seen.

The aged-rat results add a further nuance. Chronic hexarelin shifted the expression of hypothalamic somatostatin mRNA toward the levels of young animals while leaving IGF-1 unchanged (Cattaneo and colleagues, 1997). Some regulators of the axis therefore moved, which shows that absence of an IGF-1 change is not absence of any effect on the axis.

Designing a measurement of IGF-1 response

A laboratory that wants to test this question needs to decide five things before ordering any material:

  • Schedule. The literature suggests that exposure schedule decides whether GH output is sustained or desensitizes. State the schedule and justify it from a cited study.
  • Sampling. Collect GH at pulse-relevant intervals and IGF-1 at a fixed clock time, with the same fasting state and anesthesia conditions. Anesthesia and handling stress alter pituitary hormone readouts, so conscious sampling or matched conditions matter.
  • Controls. Include a vehicle group and, where the question concerns receptor specificity, an antagonist arm. The cardiac papers used a GHS-R antagonist for this purpose (Xu and colleagues, 2012).
  • Assay. Use a species-validated IGF-1 assay and record binding-protein handling. Report assay range and intra-assay variation.
  • Duration. Choose a length long enough for IGF-1 to move, and include a recovery period if desensitization is being examined.

The preparation of the material also matters. Concentration errors scale directly into exposure errors, so stock solutions should be made by the arithmetic described in the reconstitution calculator and the reconstitution calculator guide, and the lot should be matched to its certificate where one has been published (COA page).

A measurement plan, endpoint by endpoint

The table turns the observations above into a checklist. It is a design aid built from the cited papers' conditions, not a validated protocol.

EndpointTiming logicWhy the literature suggests it
Pulsatile GHFrequent sampling over several hours in conscious animalsThe mouse obesity and diabetic rat papers read GH as pulses, total output and basal level separately (Zhang and colleagues, 2018; Huang and colleagues, 2021)
Acute GH challengeBefore, during and after the exposure period, at a fixed interval after each challengeDog work showed priming at week 3 and loss of response at week 6 (Rigamonti and colleagues, 1999)
Circulating IGF-1Same clock time and fasting state at baseline and at the end, plus an intermediate point for longer studiesSlow-moving analyte; single-point comparisons are sensitive to circadian and feeding state
Hypothalamic and pituitary expressionTerminal tissue collection with matched timingAged-rat work found somatostatin mRNA shifts without an IGF-1 change (Cattaneo and colleagues, 1997)
WashoutA drug-free interval followed by a repeat challengeIn aged dogs a washout restored the GH response pattern (Cella and colleagues, 1996)

Where a study includes both a diseased and a healthy arm, report IGF-1 separately for each. The diabetic-rat paper found no significant GH elevation in the hexarelin-exposed healthy control group, while the diabetic group responded (Zhang and colleagues, 2018), so pooling the two would hide the effect.

Reading a null IGF-1 result correctly

A flat IGF-1 line does not mean hexarelin did nothing in these studies. In the same experiments GH secretion rose, hypothalamic somatostatin mRNA moved, bone-resorption and muscle indices changed in aged dogs (Cella and colleagues, 1996), and cardiac and metabolic readouts changed in other models. The finding is narrower: the circulating IGF-1 marker did not follow. A report should state the schedule, the sampling times and the assay so that readers can tell a true absence from a design that could not detect a change. It should also avoid the shortcut of equating GH pulses with IGF-1 delivery, because the data above show the two can be separated.

How hexarelin compares with other secretagogues on this endpoint

Direct head-to-head IGF-1 data are sparse. Selectivity comparisons between hexarelin and ipamorelin focus mainly on other pituitary hormones and are discussed in hexarelin vs ipamorelin, while the broader class is summarized in growth hormone secretagogues vs recombinant GH. A fair reading is that the GH-without-IGF-1 pattern has been described for the class in aged animals, not that it is unique to hexarelin.

Limits of the evidence

Most of these papers are small animal studies from a limited number of laboratories, with mixed species, ages and quantities. Several report abstracts that do not give IGF-1 values numerically, and the aged-animal studies predate current assay standards. The mouse obesity and diabetic rat papers are disease models, so their IGF-1 results may not generalize to healthy animals. Nothing in this literature supports a conclusion about any effect in people, and this article draws none.

Related reading

Frequently asked questions

Does hexarelin raise IGF-1 in animal studies?

In the aged-rat, aged-dog, diabetic-rat and obese-mouse studies reviewed here, hexarelin increased growth hormone secretion but circulating IGF-1 was unchanged or not recovered.

Why would IGF-1 not follow growth hormone?

Possible explanations from the papers include desensitization of the GH response with repeated exposure, a change in pulse pattern without a change in basal GH, disease-model physiology, and sampling windows too short for IGF-1 to move.

Which species have been used to study hexarelin and IGF-1?

Rats (aged, diabetic), beagle dogs (young and aged) and mice (obese melanocortin-4-receptor-knockout) are the main models in the cited literature.

Is desensitization seen in every hexarelin study?

No. Aged rats retained the GH response over 30 and 60 days, whereas repeated boluses in young rats and six-week administration in young dogs showed a fading response.

How should IGF-1 be sampled in a secretagogue experiment?

Use a fixed clock time and fasting state, matched anesthesia or conscious sampling, a species-validated assay, and a schedule long enough for IGF-1 to change. GH should be sampled at much shorter intervals than IGF-1.

Does hexarelin act only through the GH receptor pathway?

No. It binds GHS-R1a and also CD36 in cardiac tissue, and some cardioprotective effects were reported as GH-independent. See the hexarelin research overview for receptor details.

Can these results be applied to people?

No. They describe animal models and are not evidence about any effect in people. Hexarelin is supplied for laboratory research use only.

Related reading: Hexarelin Dose Reporting in Published Animal Studies, Hexarelin Half-Life and Stability: What Is Published, Hexarelin Reconstitution Calculator: Math and Planning.

References

  1. Cattaneo L, Luoni M, Settembrini B, Müller EE, Cocchi D. Effect of long-term administration of Hexarelin on the somatotrophic axis in aged rats. Pharmacol Res. 1997;36(1):49-54. doi:10.1006/phrs.1997.0203
  2. Cella SG, Cerri CG, Daniel S, Sibilia V, Rigamonti A, Cattaneo L, et al.. Sixteen weeks of hexarelin therapy in aged dogs: effects on the somatotropic axis, muscle morphology, and bone metabolism. J Gerontol A Biol Sci Med Sci. 1996;51(6):B439-47. doi:10.1093/gerona/51a.6.b439
  3. Rigamonti AE, Cella SG, Marazzi N, Müller EE. Six-week treatment with hexarelin in young dogs: evaluation of the GH responsiveness to acute hexarelin or GHRH administration, and of the orexigenic effect of hexarelin. Eur J Endocrinol. 1999;141(3):313-20. doi:10.1530/eje.0.1410313
  4. Conley LK, Gaillard RC, Giustina A, Brogan RS, Wehrenberg WB. Effects of repeated doses and continuous infusions of the growth hormone-releasing peptide hexarelin in conscious male rats. J Endocrinol. 1998;158(3):367-75. doi:10.1677/joe.0.1580367
  5. Zhang X, Yang JK, Chen C. Enhanced Pulsatile Growth Hormone Secretion and Altered Metabolic Hormones by in Vivo Hexarelin Treatment in Streptozotocin-Induced Diabetic Rats. Int J Mol Sci. 2018;19(10):. doi:10.3390/ijms19103067
  6. Huang Z, Lu X, Huang L, Zhang C, Veldhuis JD, Cowley MA, et al.. Stimulation of endogenous pulsatile growth hormone secretion by activation of growth hormone secretagogue receptor reduces the fat accumulation and improves the insulin sensitivity in obese mice. FASEB J. 2021;35(1):e21269. doi:10.1096/fj.202001924RR
  7. Xu X, Ding F, Pang J, Gao X, Xu RK, Hao W, et al.. Chronic administration of hexarelin attenuates cardiac fibrosis in the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol. 2012;303(6):H703-11. doi:10.1152/ajpheart.00257.2011

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.